News
Circulating biomarkers predicted melanoma survival
Adjusted hazard ratios for overall survival were 1.75 for high versus undetectable ctDNA and 1.24 for high versus low cHGF.
News
ALUR: Alectinib topped chemo in pretreated ALK-positive NSCLC
Median investigator-assessed, progression-free survival was 9.6 months with alectinib and 1.4 months with chemotherapy.
News
Alternate 2:1 sunitinib schedule showed safety gains in renal cell carcinoma
The schedule missed its primary safety endpoint but led to fewer treatment discontinuations, dose reductions, and grade 3 toxicities than was...
News
Intrauterine therapy showed promise in XLHED
Patients could sweat normally through up to 22 months of follow-up.
News
Anti-TNF drugs appear to lessen PD risk in IBD patients
Among patients with inflammatory bowel disease, anti-TNF therapy led to a 78% lower rate of Parkinson’s disease.
News
Studies eye adjuvant therapy in locally advanced rectal cancer
After a median follow-up of more than 3 years, hazard ratios for overall survival were 0.44 and 0.50, favoring adjuvant chemotherapy.
News
New regimen looks good in stage IV favorable histology Wilms
Four-year event-free survival was 79.5% among complete responders and 89% among incomplete responders.
News
MACE risk similar across arthritis subtypes
The older age of patients with rheumatoid arthritis explained most of their elevated risk of major adverse cardiovascular events.
News
KEYNOTE-054: Adjuvant pembrolizumab beat placebo in high-risk resected melanoma
CHICAGO – One-year rates of recurrence-free survival for adjuvant pembrolizumab and placebo were 75% and 61%, respectively, in a phase 3 trial of...
News
Nivolumab shows promise in early-stage resectable NSCLC
The majority of 20 patients with resectable NSCLC were alive and recurrence-free 1 year after surgery and nivolumab treatment.
News
Healthy lifestyle linked to better colon cancer survival
Five-year colon cancer survival probability was 85% for highly ACS guideline–adherent patients and 76% for patients with low adherence.
News
Americans don’t know about cancer drug shortages – but want to be told
Only 16% of respondents were aware of drug shortages, but more than 80% would want to be told about resultant substitutions with major or minor...
News
New genetic subtypes could facilitate precision medicine in DLBCL
Multiplatform analyses identified four genetic subtypes of DLBCL that show distinct mutations, gene expression signatures, and treatment responses...
News
Caffeine for apnea of prematurity found safe, effective at 11 years
At 11-year follow-up, caffeine significantly improved visuomotor, visuoperceptual, and visuospatial performance.
News
EAGLES: Smoking cessation therapy did not up cardiovascular risk
The overall rate of major adverse cardiovascular events was less than 0.5% in a study of smokers who received one of three cessation therapies or...